Zhikang Yu

810 total citations · 1 hit paper
39 papers, 471 citations indexed

About

Zhikang Yu is a scholar working on Molecular Biology, Surgery and Oncology. According to data from OpenAlex, Zhikang Yu has authored 39 papers receiving a total of 471 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 9 papers in Surgery and 9 papers in Oncology. Recurrent topics in Zhikang Yu's work include Cancer-related molecular mechanisms research (6 papers), MicroRNA in disease regulation (5 papers) and Circular RNAs in diseases (4 papers). Zhikang Yu is often cited by papers focused on Cancer-related molecular mechanisms research (6 papers), MicroRNA in disease regulation (5 papers) and Circular RNAs in diseases (4 papers). Zhikang Yu collaborates with scholars based in China, Japan and United States. Zhikang Yu's co-authors include Qingyan Huang, Heming Wu, Zhixiong Zhong, Qiuming Wang, Zuo‐Feng Zhang, Yuhong Gan, Wei Zhong, Liang Li, Qinghua Liu and Hua Zhong and has published in prestigious journals such as Frontiers in Microbiology, BMJ Open and BMC Cancer.

In The Last Decade

Zhikang Yu

39 papers receiving 465 citations

Hit Papers

Advancements and challenges in triple-negative breast can... 2024 2026 2024 10 20 30 40 50

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zhikang Yu China 13 195 156 81 73 61 39 471
María Eugenia de la Morena‐Barrio Spain 16 259 1.3× 95 0.6× 54 0.7× 86 1.2× 49 0.8× 67 798
Hideaki Tsuyoshi Japan 16 164 0.8× 91 0.6× 76 0.9× 62 0.8× 90 1.5× 42 673
Patrícia Matos Biselli-Chicote Brazil 13 306 1.6× 145 0.9× 64 0.8× 54 0.7× 50 0.8× 26 533
Tamara Djurić Serbia 13 134 0.7× 122 0.8× 85 1.0× 36 0.5× 43 0.7× 52 409
Sergiu Paşca Romania 15 216 1.1× 118 0.8× 84 1.0× 58 0.8× 33 0.5× 68 591
Guan-nan Jin China 12 269 1.4× 86 0.6× 114 1.4× 45 0.6× 81 1.3× 25 533
Çiğdem Usul Afşar Türkiye 14 123 0.6× 63 0.4× 178 2.2× 71 1.0× 75 1.2× 50 438

Countries citing papers authored by Zhikang Yu

Since Specialization
Citations

This map shows the geographic impact of Zhikang Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhikang Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhikang Yu more than expected).

Fields of papers citing papers by Zhikang Yu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhikang Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhikang Yu. The network helps show where Zhikang Yu may publish in the future.

Co-authorship network of co-authors of Zhikang Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Zhikang Yu. A scholar is included among the top collaborators of Zhikang Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhikang Yu. Zhikang Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Huang, Qingyan, et al.. (2025). Uncovering endothelial to mesenchymal transition drivers in atherosclerosis via multi-omics analysis. BMC Cardiovascular Disorders. 25(1). 104–104. 3 indexed citations
2.
Huang, Qingyan, et al.. (2024). LncRNA OIP5-AS1 Upregulates the Cyclin D2 Levels to Promote Metastasis of Breast Cancer by Targeting miR-150-5p. Applied Biochemistry and Biotechnology. 196(12). 8627–8644. 2 indexed citations
3.
Yu, Zhikang, et al.. (2024). ABO Blood Type and Pretreatment Systemic Inflammatory Response Index Associated with Lymph Node Metastasis in Patients with Breast Cancer. International Journal of General Medicine. Volume 17. 4823–4833. 2 indexed citations
5.
Liu, Qinghua, Qingyan Huang, Zhikang Yu, & Heming Wu. (2022). Clinical characteristics of non‐small cell lung cancer patients with EGFR mutations and ALK&ROS1 fusions. The Clinical Respiratory Journal. 16(3). 216–225. 6 indexed citations
6.
Liu, Hongtao, et al.. (2022). ALDH2 Polymorphism rs671 *1/*2 Genotype is a Risk Factor for the Development of Alcoholic Liver Cirrhosis in Hakka Alcoholics. International Journal of General Medicine. Volume 15. 4067–4077. 7 indexed citations
7.
Wu, Heming, Zhikang Yu, & Qingyan Huang. (2022). Characteristics of serum lipid levels in patients with hypertension: a hospital-based retrospective descriptive study. BMJ Open. 12(6). e054682–e054682. 8 indexed citations
8.
Liu, Donghua, Li Liang, Jiaquan Li, et al.. (2022). GSTP1 c.313A > G mutation is an independent risk factor for neutropenia hematotoxicity induced by anthracycline-/paclitaxel-based chemotherapy in breast cancer patients. World Journal of Surgical Oncology. 20(1). 212–212. 3 indexed citations
9.
Wu, Heming, et al.. (2022). APOE Genetic Polymorphism rs7412 T/T Genotype May Be a Risk Factor for Essential Hypertension among Hakka People in Southern China. International Journal of Hypertension. 2022. 1–9. 9 indexed citations
10.
Wu, Heming, et al.. (2021). Dihydropyrimidine dehydrogenase (DPYD) gene c.1627A>G A/G and G/G genotypes are risk factors for lymph node metastasis and distant metastasis of colorectal cancer. Journal of Clinical Laboratory Analysis. 35(11). e24023–e24023. 2 indexed citations
11.
Wu, Heming, Qingyan Huang, Xia Zhang, Zhikang Yu, & Zhixiong Zhong. (2021). Analysis of Genomic Copy Number Variation in Miscarriages During Early and Middle Pregnancy. Frontiers in Genetics. 12. 732419–732419. 12 indexed citations
12.
Zhang, Xia, Qingyan Huang, Zhikang Yu, & Heming Wu. (2021). Copy number variation characterization and possible candidate genes in miscarriage and stillbirth by next‐generation sequencing analysis. The Journal of Gene Medicine. 23(12). e3383–e3383. 7 indexed citations
13.
Huang, Qingyan, Yuhong Gan, Zhikang Yu, Heming Wu, & Zhixiong Zhong. (2021). Endothelial to Mesenchymal Transition: An Insight in Atherosclerosis. Frontiers in Cardiovascular Medicine. 8. 734550–734550. 42 indexed citations
14.
Zhong, Hua, et al.. (2020). Clinical evaluation of the T-SPOT.TB test for detection of tuberculosis infection in northeastern Guangdong Province, China. Journal of International Medical Research. 48(5). 1220723086–1220723086. 3 indexed citations
15.
Yu, Zhikang, et al.. (2020). CircRNAs open a new era in the study of cardiovascular disease (Review). International Journal of Molecular Medicine. 47(1). 49–64. 25 indexed citations
17.
Wu, Heming, Qiuming Wang, Hua Zhong, et al.. (2019). Differentially expressed microRNAs in exosomes of patients with breast cancer revealed by next‑generation sequencing. Oncology Reports. 43(1). 240–250. 46 indexed citations
19.
Zhong, Zhixiong, et al.. (2019). Circulating microRNA expression profiling and bioinformatics analysis of patients with coronary artery disease by RNA sequencing. Journal of Clinical Laboratory Analysis. 34(1). e23020–e23020. 25 indexed citations
20.
Yu, Zhikang, et al.. (2012). Clustered QTL for source leaf size and yield traits in rice (Oryza sativa L.). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026